Stephen K. Doberstein

Chief Scientific Officer, Nektar Therapeutics.

Companies

Forte Biosciences, Inc.Board member May 16, 2022 to now¹
Dicerna Pharmaceuticals (United States)Board member Feb 11, 2020 to Dec 29, 2021²
Nektar TherapeuticsChief Scientific Officer Jan 6, 2010 to Sep 9, 2019³

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Dicerna Pharmaceuticals (United States)0 shares⁴Dec 28, 2021

As of each latest filing. The line shows shares held over time.

Recent filings

Dec 28, 2021U 3,333 shares at $38.25 of Dicerna Pharmaceuticals (United States)⁴

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARForte Biosciences, Inc., Board member
2
SEC EDGARDicerna Pharmaceuticals (United States), Board member
3
SEC EDGARNektar Therapeutics, Chief Scientific Officer
4
SEC EDGARDicerna Pharmaceuticals (United States) shares after the filing of Dec 28, 2021